100 Recruiting Studies Using Pembrolizumab
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Pembrolizumab
Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies
📍 Sarah Cannon Research Institute at HealthONE — Denver, Colorado
Urinary Bladder Neoplasm
View Study & Checklist ➔Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer
📍 St. Joseph Heritage Healthcare — Santa Rosa, California
Non Small Cell Lung Cancer Metastatic
View Study & Checklist ➔9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma
📍 Brigham and Women's Hospital — Boston, Massachusetts
Salivary Gland Cancer
View Study & Checklist ➔A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer
📍 Indiana University — Indianapolis, Indiana
Carcinoma Breast Stage IV
View Study & Checklist ➔Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
📍 Exelixis Clinical Site #2 — Fullerton, California
Head and Neck Squamous Cell Carcinoma
View Study & Checklist ➔Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)
📍 Northwestern Memorial Hospital ( Site 0002) — Chicago, Illinois
Metastatic Solid Tumors
View Study & Checklist ➔Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above
📍 Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
Classical Hodgkin Lymphoma
View Study & Checklist ➔Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
📍 University of Alabama at Birmingham-Medicine ( Site 0065) — Birmingham, Alabama
Breast Neoplasms
View Study & Checklist ➔Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Stage IB Lung Non-Small Cell Carcinoma AJCC v7
View Study & Checklist ➔A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)
📍 Arizona Oncology — Tucson, Arizona
Locally Advanced or Metastatic Malignant Solid Tumors
View Study & Checklist ➔Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer
📍 NYU Perlmutter Cancer Center — New York, New York
Breast Cancer
View Study & Checklist ➔Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
📍 Moffitt Cancer Center-International Plaza — Tampa, Florida
Clinical Stage IV Cutaneous Melanoma AJCC v8
View Study & Checklist ➔Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)
📍 Fundacion ARS Medica — San Salvador de Jujuy, Jujuy Province
Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)
View Study & Checklist ➔A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study
📍 University of Colorado Cancer Center — Aurora, Colorado
Cancer
View Study & Checklist ➔Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
📍 Ironwood Cancer & Research Centers ( Site 0007) — Chandler, Arizona
Small Cell Lung Cancer
View Study & Checklist ➔A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation
📍 San Francisco VA Medical Center, San Francisco, CA — San Francisco, California
Metastatic Castration Resistant Prostate Cancer
View Study & Checklist ➔An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)
📍 University of Arizona — Tucson, Arizona
Melanoma
View Study & Checklist ➔A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer
📍 Mayo Clinic Building - Phoenix — Phoenix, Arizona
Metastatic Colorectal Cancer
View Study & Checklist ➔Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype
📍 University of California, Los Angeles — Los Angeles, California
Glioma
View Study & Checklist ➔Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer
📍 UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania
Ovarian Cancer
View Study & Checklist ➔Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors
📍 Memorial Sloan Kettering Basking Ridge — Basking Ridge, New Jersey
Solid Tumors
View Study & Checklist ➔CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer
📍 UCLA / Jonsson Comprehensive Cancer Center — Los Angeles, California
Lung Non-Small Cell Carcinoma
View Study & Checklist ➔A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer
📍 GSK Investigational Site — Plantation, Florida
Lung Cancer, Non-Small Cell
View Study & Checklist ➔Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer
📍 Moffitt Cancer Center — Tampa, Florida
GastroEsophageal Cancer
View Study & Checklist ➔Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma
📍 Northwestern University — Chicago, Illinois
B-Cell Non-Hodgkin Lymphoma
View Study & Checklist ➔Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Endometrial Endometrioid Adenocarcinoma
View Study & Checklist ➔Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)
📍 University of California at San Francisco ( Site 1008) — San Francisco, California
Carcinoma, Renal Cell
View Study & Checklist ➔Pembrolizumab Plus Olaparib in LA-HNSCC
📍 Indiana University Simon Comprehensive Cancer Center — Indianapolis, Indiana
Squamous Cell Carcinoma of Head and Neck
View Study & Checklist ➔NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma
📍 Dana-Farber Cancer Institute — Boston, Massachusetts
Melanoma
View Study & Checklist ➔NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy
📍 University of California San Francisco — San Francisco, California
Radiotherapy
View Study & Checklist ➔A Study of Pembrolizumab and Radiation Therapy in People With Mesothelioma
📍 Memorial Sloan Kettering Basking Ridge (Limited protocol activities) — Basking Ridge, New Jersey
Malignant Pleural Mesothelioma
View Study & Checklist ➔Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP]
📍 Cedars Sinai Medical Center — Los Angeles, California
HER2-positive Breast Cancer
View Study & Checklist ➔Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)
📍 University of California at San Francisco ( Site 3008) — San Francisco, California
Carcinoma, Renal Cell
View Study & Checklist ➔Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic
📍 M D Anderson Cancer Center — Houston, Texas
Advanced Malignant Solid Neoplasm
View Study & Checklist ➔Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial
📍 Thomas Hospital — Fairhope, Alabama
Advanced Melanoma
View Study & Checklist ➔Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer
📍 M D Anderson Cancer Center — Houston, Texas
Endometrial Cancer
View Study & Checklist ➔Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer
📍 M D Anderson Cancer Center — Houston, Texas
Metastatic Thyroid Gland Carcinoma
View Study & Checklist ➔Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer
📍 Stanford University — Palo Alto, California
Thyroid Cancer
View Study & Checklist ➔Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
📍 Research Site — Baltimore, Maryland
Gastric Cancer
View Study & Checklist ➔Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors
📍 University of Chicago Comprehensive Cancer Center — Chicago, Illinois
Thyroid Cancer
View Study & Checklist ➔Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)
📍 Providence Portland Medical Center — Portland, Oregon
Malignant Epithelial Neoplasms
View Study & Checklist ➔Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors
📍 University of Chicago — Chicago, Illinois
Solid Tumor
View Study & Checklist ➔A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
📍 Adventist Health System/Sunbelt, Inc. — Orlando, Florida
Melanoma
View Study & Checklist ➔A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
📍 Stanford University — San Francisco, California
Locally Advanced or Metastatic Solid Tumors
View Study & Checklist ➔Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma
📍 University of Alabama at Birmingham — Birmingham, Alabama
Astrocytoma
View Study & Checklist ➔A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
📍 Precision NextGen Oncology and Research Center — Beverly Hills, California
Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
View Study & Checklist ➔A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
📍 University of Alabama at Birmingham — Birmingham, Alabama
Renal Cell Carcinoma
View Study & Checklist ➔Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck
📍 City of Hope Comprehensive Cancer Center — Duarte, California
Head and Neck Squamous Cell Carcinoma
View Study & Checklist ➔A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
📍 The University of Alabama at Birmingham ( Site 0010) — Birmingham, Alabama
Carcinoma, Renal Cell
View Study & Checklist ➔Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors
📍 Angeles Clinic and Research Institute — Los Angeles, California
Solid Tumors
View Study & Checklist ➔Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck
📍 Moffitt Cancer Center-International Plaza — Tampa, Florida
Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
View Study & Checklist ➔A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
📍 HonorHealth Research Institute — Scottsdale, Arizona
Solid Tumor
View Study & Checklist ➔Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple Myeloma
📍 M D Anderson Cancer Center — Houston, Texas
Smoldering Plasma Cell Myeloma
View Study & Checklist ➔A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC
📍 Southern Cancer Care — Daphne, Alabama
NSCLC
View Study & Checklist ➔Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome
📍 Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
Mycosis Fungoides
View Study & Checklist ➔Neoadjuvant PD-1 Blockade in Patients with Stage IIB/C Melanoma
📍 University of Louisville — Louisville, Kentucky
Melanoma
View Study & Checklist ➔Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma
📍 Fox Chase Cancer Center - Philadelphia — Philadelphia, Pennsylvania
Urothelial Carcinoma
View Study & Checklist ➔Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
📍 Stanford School of Medicine — Stanford, California
Renal Cell Carcinoma
View Study & Checklist ➔A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001)
📍 Sanford Cancer Center ( Site 0005) — Sioux Falls, South Dakota
Advanced or Metastatic Solid Tumors
View Study & Checklist ➔Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma
📍 University of Louisville - James Graham Brown Cancer Center — Louisville, Kentucky
Head and Neck Cancer
View Study & Checklist ➔A Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumours
📍 University of Arizona Cancer Center, 3838 N. Campbell Avenue, RM 2111, Site 203 — Tucson, Arizona
Solid Tumors
View Study & Checklist ➔Lenvatinib and Pembrolizumab in People With Advanced Soft Tissue Sarcoma
📍 Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
Advanced Sarcoma
View Study & Checklist ➔A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
📍 Research Site — Gilbert, Arizona
Breast Cancer
View Study & Checklist ➔TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC
📍 Moffitt Cancer Center — Tampa, Florida
Squamous Cell Carcinoma of Head and Neck
View Study & Checklist ➔Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer
📍 Emory University — Atlanta, Georgia
Epstein-Barr Virus Positive
View Study & Checklist ➔Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab
📍 Cedars-Sinai Medical Center — Los Angeles, California
Solid Tumor, Adult
View Study & Checklist ➔Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients
📍 M D Anderson Cancer Center — Houston, Texas
High Grade Fallopian Tube Serous Adenocarcinoma
View Study & Checklist ➔A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer
📍 Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
Breast Cancer
View Study & Checklist ➔Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy
📍 Anchorage Associates in Radiation Medicine — Anchorage, Alaska
Locally Advanced Bladder Urothelial Carcinoma
View Study & Checklist ➔Breast Cancer Study of Preoperative Pembrolizumab + Radiation
📍 Cedars-Sinai Medical Center — Los Angeles, California
Breast Cancer
View Study & Checklist ➔Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder
📍 University of Chicago — Chicago, Illinois
Muscle-invasive Urothelial Cancer of the Bladder
View Study & Checklist ➔A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
📍 Mayo Clinic in Arizona - Phoenix ( Site 3554) — Phoenix, Arizona
Carcinoma, Renal Cell
View Study & Checklist ➔Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
📍 Innovative Clinical Research Institute — Whittier, California
Non-small Cell Lung Cancer
View Study & Checklist ➔Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer
📍 Research Site — Columbus, Georgia
Non Small Cell Lung Cancer
View Study & Checklist ➔Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal Cancer
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
Oropharyngeal Squamous Cell Carcinoma (SCC)
View Study & Checklist ➔Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck
📍 UCSD Moores Cancer Center — La Jolla, California
Squamous Cell Carcinoma of the Head and Neck
View Study & Checklist ➔Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma
📍 University of South Alabama Mitchell Cancer Institute — Mobile, Alabama
Advanced Melanoma
View Study & Checklist ➔Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients
📍 Ohio State University Comprehensive Cancer Center — Columbus, Ohio
Locally Advanced Melanoma
View Study & Checklist ➔BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Acute Myeloid Leukemia
View Study & Checklist ➔Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer
📍 Moffitt Cancer Center — Tampa, Florida
Metastatic Head and Neck Carcinoma
View Study & Checklist ➔Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
📍 Mayo Clinic Arizona — Phoenix, Arizona
Recurrent Head and Neck Cancer
View Study & Checklist ➔A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer
📍 Highlands Oncology Group - Duplicate 2 — Springdale, Arkansas
Non Small Cell Lung Cancer
View Study & Checklist ➔Immunotherapy Combined With Radiotherapy for Metastatic Sarcoma
📍 Chao Family Comprehensive Cancer Center, University of California, Irvine — Orange, California
Sarcoma, Soft Tissue
View Study & Checklist ➔Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)
📍 Hoag Hospital — Irvine, California
Head and Neck Cancer
View Study & Checklist ➔Pembrolizumab for the Treatment of Locally Advanced and/or Recurrent Orbital or Periocular Cutaneous Squamous Cell Carcinoma
📍 University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan
Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck
View Study & Checklist ➔Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Pleural Malignant Mesothelioma
View Study & Checklist ➔GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
📍 Alaska Oncology and Hematology LLC — Anchorage, Alaska
Malignant Solid Tumor
View Study & Checklist ➔Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas
📍 City of Hope Medical Center — Duarte, California
Anaplastic Large Cell Lymphoma
View Study & Checklist ➔A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors
📍 Sarah Cannon Research Institute at HCA HealthONE Presbyterian St. Luke's — Denver, Colorado
Advanced Solid Tumors
View Study & Checklist ➔A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Acral Lentiginous Melanoma
View Study & Checklist ➔Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Resectable Lung Non-Small Cell Carcinoma
View Study & Checklist ➔Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)
📍 Children's Hospital of Alabama ( Site 0023) — Birmingham, Alabama
Hodgkin Lymphoma
View Study & Checklist ➔A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)
📍 Moores Cancer Center ( Site 3028) — La Jolla, California
Metastatic Urothelial Carcinoma
View Study & Checklist ➔Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma
📍 Mayo Clinic Hospital in Arizona — Phoenix, Arizona
Glioblastoma
View Study & Checklist ➔PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma
📍 M D Anderson Cancer Center — Houston, Texas
Hodgkin Lymphoma
View Study & Checklist ➔In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors
📍 Los Angeles General Medical Center — Los Angeles, California
Anatomic Stage IV Breast Cancer AJCC v8
View Study & Checklist ➔Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma
📍 Mayo Clinic Hospital in Arizona — Phoenix, Arizona
Locally Advanced Urothelial Carcinoma
View Study & Checklist ➔Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.
📍 Mayo Clinic — Rochester, Minnesota
Platinum-refractory Ovarian Carcinoma
View Study & Checklist ➔Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer
📍 Stanford School of Medicine — Stanford, California
Thyroid Gland Anaplastic Carcinoma
View Study & Checklist ➔Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC
📍 Emory University/Winship Cancer Institute — Atlanta, Georgia
Invasive Breast Cancer
View Study & Checklist ➔